Business
HeartBeam to Attend JP Morgan 2026 Annual Healthcare Conference
SANTA CLARA, Calif., January 05, 2026--HeartBeam to Attend JP Morgan 2026 Annual Healthcare Conference
About this update from Heartbeam, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/6e53a3f42a5853749cd556ba56964eba"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lf5L0U0twuUb1G90oU.R7g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/6e53a3f42a5853749cd556ba56964eba","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/kcg7ka24.KoGnnIOBTavPw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/6e53a3f42a5853749cd556ba56964eba","width":1024,"height":512}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"HeartBeam Recently Received US Food and Drug Administration (FDA) Clearance for First-Ever Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment","length":159,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Pivotal Milestone Unlocks Multiple Key Initiatives in Company’s Growth Strategy","length":79,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":238,"olType":false},{"type":"text","content":"SANTA CLARA, Calif., January 05, 2026--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that it will attend the JP Morgan 2026 Annual Healthcare Conference taking place January 12-15, 2026 at the Westin St. Francis Hotel in San Francisco, CA.","length":364,"tagName":"p"},{"type":"text","content":"HeartBeam Chief Executive Officer, Robert Eno, and Chief Financial Officer, Timothy Cruickshank, will be available January 12-14 for off-site meetings with investors and potential commercialization and co-development partners to discuss the recently announced US Food and Drug Administration (FDA) 510(k) clearance for the Company’s groundbreaking 12-lead electrocardiogram (ECG) synthesis software for the assessment of arrhythmias. Unlike any single-lead or 6-lead consumer device, HeartBeam’s patented cable-free technology captures the heart’s electrical signals in three non-coplanar dimensions and synthesizes them into a 12-lead ECG representation. This allows patients to obtain an ECG reading for their arrhythmia...